Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Christine P. Limonte, Yoshio N. Hall, Subbulaxmi Trikudanathan, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 6, pp. 108204-108204
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe, Jimmy Kwon, Bin Nan, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 133-138
Open Access | Times Cited: 54
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2970-2979
Open Access | Times Cited: 36
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD
L. Parker Gregg, David J. Ramsey, Julia M. Akeroyd, et al.
American Journal of Kidney Diseases (2023) Vol. 82, Iss. 1, pp. 53-62.e1
Open Access | Times Cited: 22
Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Luis A. Rodríguez, Holly Finertie, Romain Neugebauer, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100759-100759
Open Access | Times Cited: 8
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Robert Nee, Christina M. Yuan, Andrew S. Narva, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 3, pp. 532-541
Open Access | Times Cited: 31
Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020
Benjamin G Mittman, Phuc Le, Julia Y. Payne, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 3, pp. 377-383
Closed Access | Times Cited: 6
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Jung‐Im Shin, Yunwen Xu, Alex R. Chang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 8, pp. 683-693
Closed Access | Times Cited: 6
Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure
Sara J. Cromer, Julie C. Lauffenburger, Raisa Levin, et al.
Diabetes Care (2022) Vol. 46, Iss. 1, pp. 65-74
Open Access | Times Cited: 19
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
Carl-Emil Lim, Björn Pasternak, Björn Eliasson, et al.
European Journal of Preventive Cardiology (2022) Vol. 30, Iss. 8, pp. 634-643
Open Access | Times Cited: 19
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM
Rohan Khera, Lovedeep S Dhingra, Arya Aminorroaya, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000651-e000651
Open Access | Times Cited: 12
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Optimizing Prescribing for Individuals With Type 2 Diabetes and Chronic Kidney Disease Through the Development and Validation of Algorithms for Community Pharmacists
Jennifer Morris, Marisa Battistella, Karthik Tennankore, et al.
Canadian Journal of Kidney Health and Disease (2025) Vol. 12
Open Access
Clinical Profile and Management of Patients with Newly Diagnosed Type 2 Diabetes Mellitus in Hospital Setting
Diego Muñoz Moreno, Gilberto Pérez López, Luis Antonio Álvarez-Sala Walther, et al.
Clinical Medicine Insights Endocrinology and Diabetes (2025) Vol. 18
Open Access
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand
Lynne Chepulis, Mark Rodrigues, Han Ming Gan, et al.
BMC Health Services Research (2025) Vol. 25, Iss. 1
Open Access
Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Michael G. Nanna, Quan V. Doan, Anthony N. Fabricatore, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
Retaining Race in Chronic Kidney Disease Diagnosis and Treatment
Paul F. Williams
Cureus (2023)
Open Access | Times Cited: 8
Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease
Christine P. Limonte, Julio A. Lamprea‐Montealegre, Katherine R. Tuttle
Seminars in Nephrology (2024) Vol. 44, Iss. 2, pp. 151520-151520
Closed Access | Times Cited: 2
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
L. Parker Gregg, Peter Richardson, Vijay Nambi, et al.
Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 2
Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations
Deborah O Ogunsanmi, Austin Harrison, Avinash R. Pakker, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 6, pp. 699-711
Open Access | Times Cited: 4
Best Practice Perspectives on Improving Early Detection and Management of Chronic Kidney Disease Associated With Type 2 Diabetes in Primary Care
Jennifer D. Goldman, Robert S. Busch, Eden Miller
Clinical Diabetes (2024) Vol. 42, Iss. 3, pp. 429-442
Open Access | Times Cited: 1
Paving a Path to Equity in Cardiorenal Care
Dinushika Mohottige
Seminars in Nephrology (2024) Vol. 44, Iss. 2, pp. 151519-151519
Closed Access | Times Cited: 1
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease
Aishwarya Krishnaraj, Ehab Bakbak, Hwee Teoh, et al.
Med (2023) Vol. 4, Iss. 2, pp. 130-138.e1
Open Access | Times Cited: 2
Sociodemographic disparities in the use of GLP-1 receptor agonists and SGLT-2 inhibitors among US adults with type 2 diabetes: NHANES 2005-March 2020
Benjamin G Mittman, Phuc Le, Julia Y. Payne, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top